InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
September 17 2021 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the manufacturing and
clinical development of rare cannabinoids, today announces that
Eric A. Adams, CEO of InMed, and Shane Johnson, Co-Founder of
BayMedica Inc. (“BayMedica”) will present at Tribe Public’s Webinar
Presentation and Q&A event titled “Accelerating The
Commercialization of Rare Cannabinoids”. The event is scheduled to
begin at 8.30 am Pacific/11.30 am Eastern on September 21, 2021.
To register to join the complimentary, ZOOM
webinar-based event, please visit Tribe Public LLC at
INM.TribePublic.com. Once registered, participants may begin
forwarding their questions for InMed’s & BayMedica’s management
to Tribe Public at research@tribepublic.com or share
their questions via the ZOOM chat feature during the event. Tribe
Public’s Managing Member, John F. Heerdink, Jr., will host the
event and relay all questions to management.
On September 13, 2021 InMed announced that it
had entered into a definitive agreement (“Definitive Agreement”) to
acquire BayMedica, a private company based in the U.S. that
specializes in the manufacturing and commercialization of rare
cannabinoids. The Definitive Agreement follows a previously signed
letter of intent (the "LOI") announced on June 29, 2021. The
transaction, which is subject to certain standard closing
conditions, is expected to close in the coming weeks. Upon closing,
InMed will become a global leader in the manufacturing of rare
cannabinoids, with expertise in three distinct and complementary
cannabinoid manufacturing approaches. InMed’s proprietary
cannabinoid manufacturing process, IntegraSyn™, combined with
BayMedica’s synthetic biology and chemical synthesis capabilities,
will provide InMed with complete manufacturing flexibility to
select the most appropriate, cost-effective method based on the
target cannabinoid and appropriate quality specifications for the
desired market segment. In parallel to cannabinoid manufacturing,
the combined company will continue to explore the therapeutic
potential of cannabinoids and novel cannabinoid analogs for
pharmaceutical drug development, as well as expand commercial sales
of rare cannabinoids to the consumer health and wellness
sector.
About InMedInMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of rare cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”), and is
developing IntegraSyn™ to produce pharmaceutical-grade
cannabinoids. The Company is dedicated to delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
About Tribe Public LLCTribe
Public LLC is a San Francisco, CA-based organization that hosts
complimentary worldwide webinar & meeting events in the U.S.
Tribe’s events focus on issues that the Tribe’s members care about
with an emphasis on hosting management teams and experts from
publicly traded companies from all sectors & financial
organizations that are seeking to increase awareness of their
products, progress, and plans. Tribe members primarily include
Institutions, Family Offices, Portfolio Managers, Registered
Investment Advisors, Accredited Investors, Sell Side Analysts, and
members of media. Tribe Members are encouraged to express their
interest in speakers at the Tribe Public website via the Tribe’s
FREE “Wish List” process. Visit Tribe Public’s
Website http://www.tribepublic.com/ to join the Tribe and
express your interests today
Investor Contact: Colin
ClancySenior Director, Investor RelationsT: +1 604 416 0999E:
cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding
Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking statements are frequently, but not
always, identified by words such as “expects”, “anticipates”,
“believes”, “intends”, “potential”, “possible”, “would” and similar
expressions. Such statements, based as they are on current
expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are
beyond our control. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements..
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: presenting at Tribe Public’s Webinar
Presentation; the proposed transaction with BayMedica occuring on
the announced terms if at all; the proposed transaction with
BayMedica completing and the anticipated results and potential of
BayMedica’s business and the combination of BayMedica’s business
with InMed’s business occurring; becoming a global
leader in the manufacturing of rare cannabinoids; continued
economic and market stability; delivering new therapeutic
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs; advancing IntegraSyn™ to commercial scale
production; developing IntegraSyn™ to produce pharmaceutical-grade
cannabinoids; and, developing a pipeline of cannabinoid-based
pharmaceutical drug candidates. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. Known risk factors
include, among others: regulatory filings may not be filed or
approved on a timely basis, or at all. A more complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s filings with the Security and Exchange
Commission and the most recent Annual Information Form and other
continuous disclosure filed with Canadian securities regulatory
authorities on SEDAR at www.sedar.com.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024